Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADL5945 for Opioid-induced Constipation in Chronic Noncancer Pain
NCT01275755Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2011
- Primary completion
- Jul 2011
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in opioid-induced constipation (OIC) comparing Placebo with ADL5945 0.25 mg (2 arms). Primary endpoint: Change From Baseline in the Weekly Average of Spontaneous Bowel Movements (SBMs) During Treatment. Started Jan 2011; status: completed.
02
Drugs
bevenopran
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT01275755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01275755.